2023-05-11 08:21:14 ET
- UroGen Pharma press release ( NASDAQ: URGN ): Q1 GAAP EPS of -$1.30 beats by $0.01 .
- Revenue of $17.19M (+26.8% Y/Y) beats by $0.1M .
- Cash & Cash Equivalents: As of March 31, 2023, cash, cash equivalents and marketable securities totaled $75.2 million.
- 2023 Revenue, Operating Expense and RTW Expense Guidance: The Company reiterates anticipated full year 2023 net product revenues from JELMYTO to be in the range of $76 to $86 million.
- The Company reiterates anticipated full year 2023 operating expenses in the range of $135 to $145 million, including non-cash share-based compensation expense of $6.0 to $11.0 million, subject to market conditions.
- The Company reiterates anticipated full year 2023 non-cash financing expense related to the prepaid obligation to RTW Investments in the range of $21.0 to $26.0 million. Of this amount approximately $9.9 to $11.2 million is expected to be in cash.
For further details see:
UroGen Pharma GAAP EPS of -$1.30 beats by $0.01, revenue of $17.19M beats by $0.1M